首页> 美国卫生研究院文献>Journal of Clinical Medicine >Efficacy and Safety of Tranexamic Acid in Emergency Trauma: A Systematic Review and Meta-Analysis
【2h】

Efficacy and Safety of Tranexamic Acid in Emergency Trauma: A Systematic Review and Meta-Analysis

机译:促进rAUMA促进蛋白酸的疗效和安全性:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In trauma patients, bleeding can lead to coagulopathy, hemorrhagic shock, and multiorgan failure, and therefore is of fundamental significance in regard to early morbidity. We conducted a meta-analysis to evaluate the efficacy and safety of tranexamic acid (TXA) in civil and military settings and its impact on in-hospital mortality (survival to hospital discharge or 30-day survival), intensive care unit and hospital length of stay, incidence of adverse events (myocardial infarct and neurological complications), and volume of blood product transfusion. The systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic review of the literature using PubMed, Scopus, EMBASE, Web of Science, and the Cochrane Central Register and Controlled Trials (CENTRAL) database was conducted from inception to 10 January 2021. In-hospital mortality was reported in 14 studies and was 15.5% for the TXA group as compared with 16.4% for the non-TXA group (OR = 0.81, 95% CI 0.62–1.06, I2 = 83%, p = 0.12). In a civilian TXA application, in-hospital mortality in the TXA and non-TXA groups amounted to 15.0% and 17.1%, respectively (OR = 0.69, 95% CI 0.51–0.93, p = 0.02, I2 = 78%). A subgroup analysis of the randomized control trial (RCT) studies showed a statistically significant reduction in in-hospital mortality in the TXA group (14.3%) as compared with the non-TXA group (15.7%, OR = 0.89, 95% CI 0.83–0.96, p = 0.003, I2 = 0%). To summarize, TXA used in civilian application reduces in-hospital mortality. Application of TXA is beneficial for severely injured patients who undergoing shock and require massive blood transfusions. Patients who undergo treatment with TXA should be monitored for clinical signs of thromboembolism, since TXA is a standalone risk factor of a thromboembolic event and the D-dimers in traumatic patients are almost always elevated.
机译:在创伤患者中,出血会导致凝血病,出血性休克和多核失效,因此在早期发病率方面具有根本意义。我们进行了荟萃分析,以评估宁酸(TXA)在民事化环境中的疗效和安全性及其对住院内死亡率的影响(生存到医院出院或30天存活),重症监护病房和医院长度保持,不良事件发生率(心肌梗塞和神经系统并发症)和血液产物输血量。系统审查和元分析根据首选报告项目进行系统评价和荟萃分析(PRISMA)指南进行。使用PubMed,Scopus,Embase,Web和Cochrane中央登记和控制试验(中央)数据库的系统审查是从20021年1月10日开始进行的。在14项研究中报告了院内死亡率,并且是15.5 TXA组的%与非TXA组的16.4%相比(或= 0.81,95%CI 0.62-1.06,I2 = 83%,P = 0.12)。在平民TXA应用中,TXA和非TXA组中的住院死亡率分别为15.0%和17.1%(或= 0.69,95%CI 0.51-0.93,P = 0.02,I2 = 78%)。随机对照试验(RCT)研究的亚组分析表明,与非TXA组(15.7%,或= 0.89,95%CI 0.83)相比,TXA组中医院死亡率降低了统计学上显着的降低(14.3%) -0.96,p = 0.003,I2 = 0%)。总而言之,民用申请中使用的TXA降低了院内死亡率。 TXA的应用是有益于受到休克的严重受伤患者,需要大规模的输血。应监测与TXA治疗治疗的患者用于血栓栓塞的临床症状,因为TXA是血栓栓塞事件的独立危险因素,创伤患者中的D-二聚体几乎总是升高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号